← Human Trials & Peer-Reviewed Studies
Effects of L-Carnitine on Mineral Metabolism in the Multicentre, Randomized, Double Blind, Placebo-Controlled CARNIDIAL Trial
Plain-language guide to PMID 30408788 (2018): double-blind randomized controlled trial study of L-Carnitine and Parathyroid Hormone (PTH 1-84) in 92 subjects.
Key Facts
- PMID
- 30408788
- Journal
- American journal of nephrology
- Year
- 2018
- Study type
- Randomized Controlled Trial
- Authors
- Mercadal L et al. (10 authors)
- DOI
- 10.1159/000494338
What This Study Did, in Plain Language
What Was Tested
Researchers studied L-Carnitine and Parathyroid Hormone (PTH 1-84) in this randomized controlled trial publication.
The researchers tested the effects of L-carnitine supplementation on parameters of chronic kidney disease-mineral bone disorder.
Who Took Part
The abstract describes 92 subjects taking part.
The age groups tagged for this paper are middle-aged adults and older adults, both men and women.
CARNIDIAL was a randomized, double-blinded trial having included 92 incident HD subjects for a 1-year period to receive L-carnitine versus placebo.
The L-carnitine effect on mineral metabolism was analyzed between groups by mixed linear models for repeated measurements.
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
Because people in this L-Carnitine study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
As a double-blind L-Carnitine study, the assignments were hidden from both participants and investigators until the end.
A placebo (an inactive look-alike) gave the L-Carnitine group a baseline to be compared against.
The methods mention a period of 1 year.
What Was Measured
The researchers tested the effects of L-carnitine supplementation on parameters of chronic kidney disease-mineral bone disorder.
Topics PubMed links to this paper include Calcification, Physiologic, Calcium, Carnitine, Chronic Kidney Disease-Mineral and Bone Disorder, Fibroblast Growth Factor-23, Fibroblast Growth Factors and Glucuronidase.
Author keywords: Fibroblast growth factor 23, Haemodialysis, Iron treatment, Klotho and Parathyroid hormone.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of L-Carnitine and Parathyroid Hormone (PTH 1-84) in 92 subjects over 1 year.
Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2018 (American journal of nephrology), a journal based in Switzerland.
More context: the L-Carnitine compound page and the Parathyroid Hormone (PTH 1-84) compound page, all human trials.
Our Notes on the Compounds
L-Carnitine: An amino acid derivative that carries fatty acids into mitochondria for energy production.
Parathyroid Hormone (PTH 1-84): The 84-amino-acid hormone that raises blood calcium; full-length PTH (Natpara) has been used in hypoparathyroidism. Teriparatide is its 1-34 fragment.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.